REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

20/01/2021 15:05

RNS Number : 3612M
  
GlaxoSmithKline PLC
  
20 January 2021
  
 

GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms E Walmsley




b)


Position/status


Chief Executive Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.9340


920


 




 


£13.9340


924


 




 


£13.9340


740


 




 


 


 


 




d)


Aggregated information
 


2,584




 
Aggregated volume Price


 
£13.9340




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Dr H Barron




b)


Position/status


Chief Scientific Officer and President, R&D




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 14 January 2021 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$38.1600


539


 




 


$38.1600


423


 




 


 


 


 




d)


Aggregated information
 


962




 
Aggregated volume Price


 
$38.1600




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
  




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor     
 




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.9340


195


 




 


£13.9340


241


 




 


£13.9340


233


 




 


 


 


 




d)


Aggregated information
 


669




 
Aggregated volume Price


 
£13.9340




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
  




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Conrad




b)


Position/status


SVP Human Resources




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.9340


96


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
  




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


Senior Vice President and General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.9340


137


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


Senior Vice President and General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 14 January 2021 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$38.1600


46


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
  




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.9340


102


 




 


£13.9340


72


 




 


£13.9340


101


 




 


 


 


 




d)


Aggregated information
 


275




 
Aggregated volume Price


 
£13.9340




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
  




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms S Jackson




b)


Position/status


SVP, Global Communications & CEO Office




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.9340


58


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
  




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr I Mackay




b)


Position/status


Chief Financial Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.9340


499


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




  
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr B McNamara




b)


Position/status


CEO, GSK Consumer Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 14 January 2021 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$38.1600


90


 




 


$38.1600


96


 




 


$38.1600


78


 




 


 


 


 




 


 


 


 




d)


Aggregated information
 


264




 
Aggregated volume Price


 
$38.1600




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.9340


185


 




 


£13.9340


224


 




 


£13.9340


256


 




 


 


 


 




d)


Aggregated information
 


665




 
Aggregated volume Price


 
£13.9340




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




  
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.9340


190


 




 


£13.9340


228


 




 


£13.9340


164


 




 


 


 


 




d)


Aggregated information
 


582




 
Aggregated volume Price


 
£13.9340




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
  




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharmaceuticals Supply Chain




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.9340


82


 




 


£13.9340


116


 




 


 


 


 




d)


Aggregated information
 


198




 
Aggregated volume Price


 
£13.9340




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
  




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms K Terrell




b)


Position/status


Chief Digital & Technology Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 14 January 2021 on ADSs held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$38.1600


32


 




 


$38.1600


114


 




 


$38.1600


79


 




 


 


 


 




d)


Aggregated information
 


225




 
Aggregated volume Price


 
$38.1600




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




  
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.9340


128


 




 


£13.9340


133


 




 


£13.9340


94


 




 


 


 


 




d)


Aggregated information
 
 


355




Aggregated volume Price


£13.9340




e)


Date of the transaction


2021-01-18




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHEBLFLFFLBBBF